Abstract
Purpose: The purpose of this study is to identify factors associated with severe late toxicity and prognosis in women with locally advanced cervical cancer treated with definitive chemoradiation (CRT) and high dose rate (HDR) radiation therapy boost. An increased rate of GI toxicity when Bevacizumab is administered in combination with high doses of abdominal radiation therapy such as stereotactic body radiotherapy (SBRT) has been demonstrated in other malignancies. Our aim is to compare the risk of Grade 3+ toxicity in patients who receive Bevacizumab after HDR brachytherapy in comparison with other risk factors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
